Aster Capital Management DIFC Ltd Takes Position in Moderna, Inc. (NASDAQ:MRNA)

Aster Capital Management DIFC Ltd acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 11,987 shares of the company's stock, valued at approximately $498,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. State Street Corp boosted its stake in shares of Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company's stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC boosted its position in Moderna by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock valued at $300,219,000 after acquiring an additional 171,774 shares in the last quarter. Wellington Management Group LLP boosted its position in Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company's stock valued at $349,166,000 after acquiring an additional 906,114 shares in the last quarter. Norges Bank purchased a new position in shares of Moderna in the 4th quarter valued at $163,833,000. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Moderna by 9.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,344,203 shares of the company's stock worth $97,472,000 after acquiring an additional 211,426 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Stock Up 6.9 %

Shares of MRNA stock traded up $1.70 on Friday, hitting $26.20. The company had a trading volume of 10,999,018 shares, compared to its average volume of 7,181,061. The firm has a market cap of $10.13 billion, a P/E ratio of -2.82 and a beta of 2.23. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $170.47. The company has a 50-day moving average price of $31.56 and a 200-day moving average price of $41.01.

Remove Ads

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Royal Bank of Canada reiterated a "sector perform" rating and issued a $40.00 target price on shares of Moderna in a report on Tuesday, February 18th. Morgan Stanley reduced their price objective on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research note on Wednesday. Evercore ISI set a $50.00 target price on shares of Moderna in a research note on Friday, February 14th. The Goldman Sachs Group downgraded Moderna from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $99.00 to $51.00 in a research report on Wednesday, January 29th. Finally, Bank of America lowered their price objective on Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research report on Tuesday, February 11th. Four investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $58.70.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.